| Literature DB >> 33013862 |
Isaac M Barber-Axthelm1, Stephen J Kent1,2,3, Jennifer A Juno1.
Abstract
Chronic HIV infection causes systemic immune activation and dysregulation, resulting in the impairment of most T-cell subsets including MAIT cells. Multiple human cohort studies demonstrate MAIT cells are selectively depleted in the peripheral blood and lymphoid tissues during HIV infection, with incomplete restoration during suppressive antiretroviral therapy. Because MAIT cells play an important role in mucosal defense against a wide array of pathogens, fully reconstituting the MAIT cell compartment in ART-treated populations could improve immunity against co-infections. Non-human primates (NHPs) are a valuable, well-described animal model for HIV infection in humans. NHPs also maintain MAIT cell frequencies more comparable to humans, compared to other common animal models, and provide a unique opportunity to study MAIT cells in the circulation and mucosal tissues in a longitudinal manner. Only recently, however, have NHP MAIT cells been thoroughly characterized using macaque-specific MR1 tetramer reagents. Here we review the similarities and differences between MAIT cells in humans and NHPs as well as the impact of SIV/SHIV infection on MAIT cells and the potential implications for future research.Entities:
Keywords: HIV/SIV infection; HIV/TB co-infection; MAIT cells; MR1; comparative immunology; non-human primate
Mesh:
Substances:
Year: 2020 PMID: 33013862 PMCID: PMC7461791 DOI: 10.3389/fimmu.2020.02038
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Comparison of MAIT cell tissue frequencies between humans, non-human primates, and mice.
| Human (% of CD3+); Mean (range) | Non-human primate (% of CD3+); Mean (range) | Mouse (% of CD3+); Mean (range) | |
| Blood | 2.6 (0.1–9.2) | 1–2 (0.026–6.5) | 0.1 |
| ( | ( | ( | |
| Liver | 20–50 | 4–7 (0.5–17) | 0.60 |
| ( | ( | ( | |
| Gastrointestinal tract | 1.5–10 | 0.02–3 | 0.70 |
| ( | ( | ( | |
| Lung | 2–4 | 1.10 | 3.30 |
| ( | ( | ( | |
| Lymph node | 1 | 0.03–0.2 | 0.20 |
| ( | ( | ( |
Comparison of MAIT stimulation responses between humans, non-human primates, and mice.
| Human (% of CD3+); Mean (range) | Non-human primate (% of CD3+); Mean (range) | |
| 5-OP-RU/5-A-RU | CD69: ∼95 TNFα: 14–18 IFNγ: 20–60 | CD69: 20–80 TNFα: 5–13 IFNγ: 0.1–4 |
| ( | ( | |
| PMA/Ionomycin | TNFα: ∼80–95 IFNγ: ∼0.5–5 IL-17: ∼4–10 | TNFα: ∼20–80 IFNγ: ∼5–80 IL-17: ∼7–20 |
| ( | ( | |
| TNFα: 10–50 IFNγ: 10–75 | TNFα: ∼25–35 IFNγ: ∼20–35 | |
| ( | ( |
FIGURE 1Species-specific variations in MAIT cell activation via MR1-mediated presentation of bacterial-derived vitamin B metabolites to the MAIT cell TCR, as well as IL-12/IL-18 mediated cytokine stimulation. Activation results in MAIT cell proliferation, cell surface marker upregulation associated with cell activation, and release of proinflammatory cytokines and granzyme B. Both human and NHP MAIT cells upregulate CD69 and CD107a, and produce IFNγ and TNFα. Human MAIT cells have also been shown to upregulate CD40L and 4-1BB. In contrast, murine MAIT cells have been shown to upregulate CD69 and CD25, and predominately produce IL-17 when activated.